Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Cash from Investing Activities (2016 - 2025)

Avanos Medical's Cash from Investing Activities history spans 11 years, with the latest figure at -$7.6 million for Q4 2024.

  • For Q4 2024, Cash from Investing Activities fell 109.38% year-over-year to -$7.6 million; the TTM value through Dec 2024 reached -$27.5 million, down 227.31%, while the annual FY2025 figure was -$60.6 million, 120.36% down from the prior year.
  • Cash from Investing Activities for Q4 2024 was -$7.6 million at Avanos Medical, up from -$12.0 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $81.0 million in Q4 2023 and bottomed at -$121.7 million in Q1 2022.
  • The 5-year median for Cash from Investing Activities is -$5.4 million (2020), against an average of -$9.3 million.
  • The largest annual shift saw Cash from Investing Activities plummeted 2035.09% in 2022 before it soared 1753.06% in 2023.
  • A 5-year view of Cash from Investing Activities shows it stood at -$5.1 million in 2020, then grew by 7.84% to -$4.7 million in 2021, then decreased by 4.26% to -$4.9 million in 2022, then skyrocketed by 1753.06% to $81.0 million in 2023, then tumbled by 109.38% to -$7.6 million in 2024.
  • Per Business Quant, the three most recent readings for AVNS's Cash from Investing Activities are -$7.6 million (Q4 2024), -$12.0 million (Q3 2024), and -$5.9 million (Q2 2024).